Extracts of
The present invention relates to plant extracts, specifically, the extracts of Chinese medicine Chenopodium ambrosioides L . and the composition comprising thereof. The extracts of Chinese medicine Chenopodium ambrosioides L . are prepared by conventional methods for the extraction of volatile oil, and can be used to treat Helicobacter Pylori -induced diseases of digestive system, such as gastritis, gastric ulcer, etc., with easy availability of raw materials, simple preparations, prominent effects, and less side-effect.
1. An essential oil extract from whole herbs including the seed-bearing spike of Chenopodium ambrosioides L ., wherein the extract comprises the following components by weight: α-terpinene 15-35%, p-cymene 15-25%, ascaridole 10-20% and α-terpinolene 32-40%.
2. The essential oil extract of Chenopodium ambrosioides L . according to claim 1 , wherein the extract comprises the following components by weight: α-terpinene 20-30%, p-cymene 18-22%, ascaridole 12-18% and α-terpinolene 32-35%.
3. The essential oil extract of Chenopodium ambrosioides L . according to claim 2 , wherein the extract further comprises the following components by weight: γ-terpinene 0.5-0.7%, and/or limonene 0.6-0.8%.
4. The essential oil extract of Chenopodium ambrosioides L . according to claim 1 , wherein the extract further comprises the following components by weight: γ-terpinene 0.5-0.7%, and/or limonene 0.6-0.8%.
5. A pharmaceutical composition comprising
an essential oil extract from whole herbs including the seed-bearing spike of Chenopodium ambrosioides L ., wherein the extract comprises the following components by weight: α-terpinene 15-35%, p-cymene 15-25%, ascaridole 10-20% and α-terpinolene 32-40%, and
pharmaceutically acceptable adjuvants.
6. The pharmaceutical composition of claim 5 , wherein the extract comprises the following components by weight: α-terpinene 20-30%, p-cymene 18-22%, ascaridole 12-18% and α-terpinolene 32-35%.
7. The pharmaceutical composition of claim 6 , wherein the extract further comprises the following components by weight: γ-terpinene 0.5-0.7%, and/or limonene 0.6-0.8%.
8. The pharmaceutical composition of claim 5 , wherein the extract further comprises the following components by weight: γ-terpinene 0.5-0.7%, and/or limonene 0.6-0.8%.
9. The pharmaceutical composition according to claim 5 , wherein the composition is prepared into various dosage forms.
10. The pharmaceutical composition according to claim 9 , wherein the dosage form is gelatin pills.
11. The pharmaceutical composition according to claim 10 , wherein the weight ratio of the extract of Chenopodium ambrosioides L . to vegetable oil is 1:1-3, and said vegetable oil is used as the pharmaceutically acceptable carrier for solvating and diluting said extract.
12. The pharmaceutical composition according to claim 10 , wherein the gelatin pills comprise a coating material, and the coating material includes gelatin and plasticizer, and the plasticizer is selected from the group consisting of glycerine, xylitol, sorbitol, and hydrogenated corn steep liquor.
13. The pharmaceutical composition according to claim 9 , wherein the dosage forms is self-emulsifying preparations, and the weight ratio of the components is extract of Chenopodium ambrosioides L . 1-95%, rapeseed salad oil 4-39%, surfactant 1-45%, and cosurfactant 0-15%.
14. The pharmaceutical composition of claim 13 , wherein the extract further comprises the following components by weight: γ-terpinene 0.5-0.7%, and/or limonene 0.6-0.8%.
15. The pharmaceutical composition according to claim 13 , wherein the surfactant is selected from the group consisting of condensates of polyoxyethylene and castor oil, condensates of polyoxyethylene and hydrogenated castor oil, polysorbate, and phospholipids, and the cosurfactant is selected from the group consisting of ethanol, glycol, propanediol, n-butanol, isopropanol, polyglycol 4000, and polyglycol 6000.
16. The pharmaceutical composition according to claim 15 , wherein the condensate of polyoxyethylene and castor oil is selected from polyoxyethylene (35) castor oil and polyoxyethylene (60) castor oil; the condensate of polyoxyethylene and hydrogenated castor oil is selected from polyoxyethylene (35) hydrogenated castor oil and polyoxyethylene (60) hydrogenated castor oil; the polysorbate is selected from polysorbate 60 and polysorbate 80; the phospholipid is selected from the group consisting of yolk lecithin, soybean lecithin, dipalmitoyl phosphatidylcholine, distearoyl phosphatidylcholine, and dimyristoyl phosphatidylcholine.
17. An essential oil extract from whole herbs including the seed-bearing spike of Chenopodium ambrosioides L ., wherein the extract comprises the following components by weight: α-terpinene 15-35%, p-cymene 15-25%, ascaridole 10-20% and α-terpinolene 32-40%, and the extract of Chenopodium ambrosioides L . is obtained by steam distillation as follows:
adding whole herbs including the seed-bearing spike of Chenopodium ambrosioides L . to a distillatory kettle;
applying steam to a collector to pass over the whole herbs including the seed-bearing spike of Chenopodium ambrosioides L . in the distillatory kettle;
keeping the extraction temperature at 85-100° C.; and
collecting the essential oil extract from the Chenopodium ambrosioides L .
18. The essential oil extract of Chenopodium ambrosioides L . according to claim 17 , wherein the extract comprises the following components by weight: α-terpinene 20-30%, p-cymene 18-22%, ascaridole 12-18% and α-terpinolene 32-35%.
19. The essential oil extract of Chenopodium ambrosioides L . according to claim 17 , wherein the extract further comprises the following components by weight: γ-terpinene 0.5-0.7%, and/or limonene 0.6-0.8%.
20. The essential oil extract of Chenopodium ambrosioides L . according to claim 18 , wherein the extract further comprises the following components by weight: γ-terpinene 0.5-0.7%, and/or limonene 0.6-0.8%.